Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Metamizole→

Metamizole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50567-35-6
Molecular formula
C13H17N3O4S
Molecular weight
311.36 g/mol
Drug class
Pyrazolone analgesic and antipyreticnon-opioid pain reliever with spasmolytic activity
Mechanism of action
The exact mechanism is not fully established. Metamizole and its metabolites produce analgesic, antipyretic and spasmolytic effects; proposed actions include central and peripheral modulation of prostaglandin pathways and other pain-signalling mechanisms.
Indications / reported uses
  • Acute severe pain following trauma or surgery
  • Painful colic and other severe pain when alternative measures are inadequate or contraindicated
  • High fever unresponsive to other measures, only in jurisdictions and formulations where authorised; use is restricted in some countries because of agranulocytosis risk

Sources: British Journal of Clinical Pharmacology review (2025) · Metamizole sodium product information (manufacturer dossier; indications subject to national authorisation) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Metamizole Environmental Risk Assessment (ERA) (the Metamizole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.